DXCM CMS decision and 15-Day sensor rollout eyed to lift 2027 growth
DXCM says CMS review tied to type 2 non-insulin coverage, plus its 15-Day sensor and AI features, could support market expansion by mid-2027 and improve growth and margins.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.